72 C. Biane and F. Delaplace
- Botting, G.M., Rastogi, I., Chhabra, G., Nlend, M., Puri, N.: Mechanism of resis-
tance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase
inhibitors in non-small cell lung cancer. PloS one 10 (8), e0136155 (2015) - Burga, L.N., Hai, H., Juvekar, A., Tung, N.M., Troyan, S.L., Hofstatter, E.W.,
Wulf, G.M.: Loss of BRCA1 leads to an increase in epidermal growth factor recep-
tor expression in mammary epithelial cells, and epidermal growth factor recep-
tor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Breast Cancer Res. 13 (2), R30 (2011) - Ciliberto, A., Nov ́ak, B., Tyson, J.J.: Steady states and oscillations in the
p53/Mdm2 network. Cell Cycle 4 (3), 488–493 (2005) - Creixell, P., Schoof, E.M., Simpson, C.D., Longden, J., Miller, C.J., Lou, H.J.,
Perryman, L., Cox, T.R., Zivanovic, N., Palmeri, A., Wesolowska-Andersen, A.,
Helmer-Citterich, M., Ferkinghoff-Borg, J., Itamochi, H., Bodenmiller, B., Erler,
J.T., Turk, B.E., Linding, R.: Kinome-wide decoding of network-attacking muta-
tions rewiring cancer signaling. Cell 163 (1), 202–217 (2015) - Croce, C.M.: Oncogenes and cancer. New Engl. J. Med. 358 (5), 502–511 (2008).
PMID: 18234754 - Csermely, P., Korcsm`aros, T., Kiss, H.J.M., London, G., Nussinov, R.: Structure
and dynamics of molecular networks: a novel paradigm of drug discovery: a com-
prehensive review. Pharmacol. Therapeutics 138 (3), 333–408 (2013) - Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N.J., Johnson, D.A., Richardson,
T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al.: Targeting
the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature
434 (7035), 917–921 (2005) - Gupta, S.: Molecular signaling in death receptor and mitochondrial pathways of
apoptosis (review). Int. J. Oncol. 22 (1), 15–20 (2003) - Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: the next generation. Cell
144 (5), 646–674 (2011) - Kaelin, W.G.: The concept of synthetic lethality in the context of anticancer ther-
apy. Nat. Rev. Cancer 5 (9), 689–98 (2005) - Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Charles, L., Xie, M.,
Zhang, Q., McMichael, J.F., Wyczalkowski, M.A., et al.: Mutational landscape and
significance across 12 major cancer types. Nature 502 (7471), 333–339 (2013) - Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., Morishima, K.: KEGG: new
perspectives on genomes, pathways, diseases and drugs. Nucl. Acids Res. 45 (D1),
D353–D361 (2017) - Kolch, W., Halasz, M., Granovskaya, M., Kholodenko, B.N.: The Dynamic Control
of Signal Transduction Networks in Cancer Cells. Nature Publishing Group (2015) - Layek, R., Datta, A., Bittner, M.: ER Dougherty: cancer therapy design based on
pathway logic. Bioinformatics 27 (4), 548–555 (2011) - Lee, J.Y., Hong, M., Kim, S.T., Park, S.H., Kang, W.K., Kim, K.-M., Lee, J.: The
impact of concomitant genomic alterations on treatment outcome for trastuzumab
therapy in HER2-positive gastric cancer. Sci. Rep. 5 , 9289 (2015) - Lin, P.-C.K., Khatri, S.P.: Application of Max-SAT-based ATPG to optimal cancer
therapy design. BMC Genomics 13 (Suppl 6), S5 (2012) - Livraghi, L., Garber, J.E.: PARP inhibitors in the management of breast cancer:
current data and future prospects. BMC Med. 13 (1), 1 (2015) - Lodish, H., Zipursky, S.L.: Molecular cell biology. Biochem. Mol. Biol. Educ. 29 ,
126–133 (2001)